[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Meiragtx Holdings Plc (MGTX)

Meiragtx Holdings Plc (MGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,309,506
  • Shares Outstanding, K 92,610
  • Annual Sales, $ 81,390 K
  • Annual Income, $ -114,200 K
  • EBIT $ -105 M
  • EBITDA $ -91 M
  • 60-Month Beta 1.20
  • Price/Sales 16.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.87% (-6.73%)
  • Historical Volatility 68.72%
  • IV Percentile 13%
  • IV Rank 9.40%
  • IV High 654.36% on 02/10/26
  • IV Low 63.34% on 06/17/26
  • Expected Move (DTE 8) 0.04 (0.31%)
  • Put/Call Vol Ratio 0.96
  • Today's Volume 45
  • Volume Avg (30-Day) 277
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,796
  • Open Int (30-Day) 2,472
  • Expected Range 13.82 to 13.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 4
  • High Estimate $-0.08
  • Low Estimate $-0.51
  • Prior Year $-0.48
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.90 +53.31%
on 06/11/26
15.35 -11.11%
on 07/07/26
+4.44 (+48.15%)
since 06/09/26
3-Month
8.75 +55.94%
on 04/29/26
15.35 -11.11%
on 07/07/26
+4.31 (+46.09%)
since 04/09/26
52-Week
6.62 +106.12%
on 03/05/26
15.35 -11.11%
on 07/07/26
+5.28 (+63.02%)
since 07/09/25

Most Recent Stories

More News
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment Following regulatory approval, Oberland Capital to receive low single-digit capped royalties...

MGTX : 13.68 (-3.25%)
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee...

MGTX : 13.68 (-3.25%)
MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia...

MGTX : 13.68 (-3.25%)
MeiraGTx: Wall Street Celebrates Revenue While Ignoring the Cash Drain

Barchart Research What to Expect from MGTX Earnings MGTX Generated May 11, 2026 Current Price $9.90 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 7.24% MeiraGTx: Wall Street Celebrates...

MGTX : 13.68 (-3.25%)
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten...

MGTX : 13.68 (-3.25%)
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)...

MGTX : 13.68 (-3.25%)
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts...

MGTX : 13.68 (-3.25%)
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for...

MGTX : 13.68 (-3.25%)
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to...

MGTX : 13.68 (-3.25%)
MeiraGTx Faces Mounting Losses as Analysts Await Fourth Quarter Results

Barchart Research What to Expect from MGTX Earnings MGTX Generated March 25, 2026 Current Price $7.62 EPS Estimate $-0.60 Consensus Rating Strong Buy Average Move 7.98% MeiraGTx Faces Mounting Losses as...

MGTX : 13.68 (-3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR,...

See More

Key Turning Points

3rd Resistance Point 15.82
2nd Resistance Point 15.29
1st Resistance Point 14.71
Last Price 13.68
1st Support Level 13.60
2nd Support Level 13.07
3rd Support Level 12.49

See More

52-Week High 15.35
Last Price 13.68
Fibonacci 61.8% 12.02
Fibonacci 50% 10.99
Fibonacci 38.2% 9.95
52-Week Low 6.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.